Personalized mRNA Vaccine Shows 87% Survival Rate in Pancreatic Cancer Patients Six Years Later

Pancreatic cancer is one of the few diseases where even a diagnosis caught early enough for surgery still carries an 80 percent chance of the cancer coming back. Its five-year survival rate sits at around 13 percent. Decades of research have barely moved that number. Now, a personalized mRNA vaccine tested at Memorial Sloan Kettering Cancer Center is producing results that oncologists are calling genuinely encouraging: seven of eight patients whose immune systems responded to the vaccine are still alive up to six years after treatment. For a cancer with survival odds this grim, that number carries real weight.

Why Pancreatic Cancer Has Been So Hard to Treat

Pancreatic cancer earns its reputation as one of the deadliest cancers through a combination of factors that make it resistant to nearly every standard treatment available. Chemotherapy, radiation, targeted therapy, and current immunotherapies have all shown limited effectiveness against the disease. Pancreatic cancer is the third leading cause of cancer-related death in the United States and is expected to rise to second place by 2030.

Part of what makes it so difficult to treat immunologically is that pancreatic tumors carry relatively few neoantigens, the molecular flags that help the immune system identify cancer cells as foreign and worthy of attack. In most patients, the immune system does not register pancreatic cancer cells as a threat. Without that recognition, there is no immune response to build on, and standard immunotherapy drugs called checkpoint inhibitors, which work by removing molecular brakes from the immune system, have little to work with.

Pancreatic cancer has also more than doubled in global incidence over the past three decades, rising from around 196,000 new cases worldwide in 1990 to over 510,000 in 2022. About 90 percent of patients are diagnosed too late for surgery, which remains one of the only realistic paths toward a cure. In the most advanced stages, the five-year survival rate drops to 3.2 percent.

A Decade of Research Led to One Key Question

Vinod Balachandran, MD, principal investigator of the trial and Director of the Olayan Center for Cancer Vaccines at MSK, began building toward this research a decade ago by asking a different question from most of his peers. Rather than focusing on why most pancreatic cancer patients die, he focused on why a small number survive.

His team analyzed tumor tissue from long-term survivors and found a consistent pattern: their tumors were densely populated with T cells, the immune system’s precision-attack units. Something in those tumors was drawing T cells in and directing them to fight. Balachandran traced that signal to neoantigens, the unique proteins produced when tumor cells accumulate genetic mutations during cell division.

In most pancreatic cancer patients, neoantigens go undetected by immune cells. But in rare long-term survivors, the neoantigens were different. They did not evade immune detection. They effectively uncloaked the tumor to T cells, triggering an attack. More striking still, researchers found that the neoantigen-recognizing T cells kept circulating in the blood of these survivors for up to 12 years after surgical removal of their tumors. Those T cells had a lasting memory of the cancer as a threat. Balachandran published those findings in Nature in November 2017.

The logical next step was finding a way to give other patients those same immune advantages artificially, using a vaccine.

How the Personalized Vaccine Works

Balachandran connected with Professor Uğur Şahin, co-founder and CEO of BioNTech, whose team was developing individualized neoantigen-based mRNA therapies for multiple solid tumors. In late 2017, Balachandran traveled to Germany to discuss whether mRNA technology could be used to build personalized cancer vaccines for pancreatic cancer patients.

Autogene cevumeran, the resulting vaccine, works by exploiting the same biological logic that Balachandran had observed in long-term survivors. After a patient’s tumor is surgically removed, it is shipped to BioNTech in Germany and genetically sequenced. Researchers identify up to 20 mutations with the highest likelihood of producing neoantigens that look foreign to the immune system. A personalized mRNA vaccine is then designed and manufactured for that specific patient, encoding instructions for the patient’s own cells to produce those neoantigens and trigger an immune response. Each vaccine is different because each tumor is different.

Once infused into the patient’s bloodstream, the vaccine teaches the immune system to recognize and attack cancer cells carrying those mutations. If any remaining cancer cells survive surgery or return later, the trained immune system has memory of them as a threat.

What the Phase 1 Trial Found

Sixteen patients with operable pancreatic cancer participated in the phase 1 trial. All received autogene cevumeran after surgery, alongside atezolizumab, a checkpoint inhibitor immunotherapy drug, and chemotherapy. Balachandran presented long-term follow-up results at the 2026 Annual Meeting of the American Association for Cancer Research.

Eight of the 16 patients mounted a measurable immune response to the vaccine. Their immune systems produced tumor-specific T cells that recognized cancer cells as foreign. Of those eight responders, seven, or 87.5 percent, were still alive between four and six years after surgery at the time of the follow-up report. Among the eight patients who did not respond to the vaccine, only two, or 25 percent, were still alive, with a median survival time of 3.4 years.

Researchers tracking the immune response found that patients who responded to the vaccine produced both CD8+ T cells, which directly kill cancer cells, and CD4+ T cells, which boost and sustain the immune response over time. Both cell types were still present and active up to six years after vaccination, with no signs of declining. An effective cancer vaccine likely needs to activate both cell types to produce a response that is both strong and lasting.

Computational biologist Benjamin Greenbaum, PhD, Co-Director of the Olayan Center for Cancer Vaccines and a key figure in analyzing the immune response data, explained that designing cancer vaccines requires selecting the right targets on each patient’s tumor and getting the immune system to respond strongly and keep fighting over time. That challenge is far harder in cancers where other immunotherapies have failed.

Two Patients Who Lived to Tell Their Stories

Donna Gustafson was the first person to enroll in the autogene cevumeran trial, joining in late 2019 at age 66 after being diagnosed with pancreatic cancer while visiting her daughter in Australia. After returning to the United States and coming to MSK, she learned she was eligible for the trial. Her tumor was removed surgically, genetically analyzed, and used to build a personalized vaccine. She received immunotherapy, eight doses of the vaccine, chemotherapy, and a final vaccine dose over the following months.

Now 72, Donna and her husband celebrated their 50th wedding anniversary in Sicily last year and continue to travel and spend time with their three daughters and six grandchildren. She described the vaccine as having very few side effects, while the chemotherapy was harder on her body. She called her outcome a miracle.

Donald Sarcone, a certified public accountant from Staten Island, was diagnosed in 2020 at age 60 after his wife and daughter noticed he had turned yellow. An endoscopy found a pancreatic tumor blocking his bile duct. He enrolled in the trial without hesitation. Now 67, his regular checkups show no sign that the cancer has returned. He plays tennis once a week and travels regularly, saying he sometimes forgets what he went through because he is healthy and has moved on with his life.

A Global Phase 2 Trial Is Now Underway

Phase 1 clinical trials are designed primarily to test safety and observe initial signals, not to establish definitive efficacy in large populations. Sixteen patients are a small sample, and researchers are clear that more work is needed. The patients in this trial also had cancer detected at a relatively early stage, which is unusual for pancreatic cancer, making it uncertain whether results would look the same in a broader population.

Based on the phase 1 results, a global phase 2 trial sponsored by Genentech in collaboration with BioNTech is now testing autogene cevumeran in approximately 260 patients at MSK and sites around the world. That trial began in 2023 and is estimated to be completed by 2031. A larger trial population across multiple sites will produce clearer evidence about how broadly the vaccine works and which patients are most likely to benefit.

In parallel, MSK researchers are testing ELI-002 2P, a ready-made vaccine targeting KRAS gene mutations, which drive most pancreatic cancers. Unlike autogene cevumeran, a KRAS-targeting vaccine could be mass-produced and stored for immediate use rather than manufactured individually for each patient. Phase 1 results show the vaccine helps some patients live longer without cancer returning, and a phase 2 trial led by Dr. Eileen O’Reilly and surgical oncologist Kevin Soares is expected to open in 2026.

MSK is also building in-house mRNA vaccine manufacturing infrastructure in Manhattan to expand patient access to personalized vaccine trials across multiple cancer types, reducing dependence on shipping tumors internationally and accelerating the time from diagnosis to treatment.

What This Means for the Future of Cancer Treatment

The mRNA vaccine technology behind autogene cevumeran is the same platform used to produce COVID-19 vaccines, applied now to a cancer context. For pancreatic cancer in particular, the results suggest that a cancer long thought to be resistant to immune-based treatment is not immune to the immune system entirely. It just needs the immune system to be shown more clearly what to fight.

Robert Vonderheide, President-elect of AACR, framed the broader possibility: if the immune system can be awakened to prevent cancer from coming back in pancreatic cancer, that same strategy could apply to more patients and more cancer types. Balachandran has spent his career asking not why patients die but why they live, treating the immune system as a potential weapon rather than a bystander. Six years of survival data from a cancer with a 13 percent five-year survival rate suggests that framing is producing real results.

My Personal RX on Supporting Your Body Through Cancer Prevention and Treatment

As a doctor and patient advocate, I find these results meaningful for a very specific reason: they confirm that the immune system is capable of fighting even the most aggressive cancers when it is given the right information. That is a lesson that applies beyond clinical trials. Every day, your immune system is performing cancer surveillance, looking for abnormal cells before they develop into tumors. Whether that system runs at its best or breaks down under the weight of chronic inflammation, poor nutrition, sleep deprivation, and stress comes down to choices made long before any diagnosis. I want every person reading this to understand that supporting your immune health is not a passive activity. It is active cancer prevention, performed one meal, one night of sleep, and one healthy habit at a time. And if you or someone you love is facing a cancer diagnosis, know that clinical trials like this one exist and are worth asking about.

1. Eat to Reduce Systemic Inflammation: Chronic inflammation creates the cellular environment where cancer develops and spreads. Build your diet around anti-inflammatory foods, including fatty fish, leafy greens, berries, extra virgin olive oil, and cruciferous vegetables. Limit processed foods, red meat, refined sugar, and seed oils that promote inflammatory signaling at the cellular level.
   
2. Know Your Pancreatic Cancer Risk Factors: Risk factors for pancreatic cancer include long-term smoking, type 2 diabetes, chronic pancreatitis, obesity, and a family history of the disease. If any of these apply to you, speak with your doctor about monitoring and early detection strategies.
   
3. Ask About Clinical Trials if You Receive a Cancer Diagnosis: Trials like autogene cevumeran exist and are actively enrolling patients. When facing a cancer diagnosis, ask your oncologist whether any clinical trials match your specific cancer type, stage, and genetic profile. Many patients who enroll early benefit from access to treatments not yet available outside trial settings.
   
4. Protect Deep Sleep for Immune Maintenance: Your immune system does its most intensive cancer surveillance and cellular repair during deep sleep. Chronic sleep deprivation raises inflammatory cytokines and weakens natural killer cell activity. Sleep Max combines magnesium, GABA, 5-HTP, and taurine to support restorative deep sleep and keep your immune system running at full capacity.
   
5. Fill the Nutritional Gaps That Weaken Immune Defense: Deficiencies in vitamin D, selenium, zinc, omega-3 fatty acids, and B vitamins all impair immune cell production and function. Download The 7 Supplements You Can’t Live Without, a free guide covering the nutrients most likely to be deficient after 40 and how to choose quality supplements that actually deliver results.
   
6. Move Daily to Reduce Cancer Risk: Physical activity lowers circulating insulin, estrogen, and inflammatory markers that raise cancer risk across multiple tumor types. Aim for at least 150 minutes of moderate aerobic activity per week, combined with two sessions of resistance training. Exercise also improves immune cell circulation and reduces the chronic low-grade inflammation that precedes many cancers.
   
7. Eliminate Tobacco and Minimize Alcohol: Smoking is a known risk factor for pancreatic cancer and over a dozen other cancer types. Alcohol is a Group 1 carcinogen that raises risk for multiple cancers, including breast, colon, and liver. Eliminating or minimizing both substances measurably reduces cumulative carcinogen exposure.
   
8. Stay Current With Cancer Screenings and Genetic Testing: Early detection gives the immune system and medical treatment the best possible odds. Know your family history. Ask your doctor whether genetic testing for inherited cancer mutations is appropriate for you. And stay current with age-appropriate cancer screenings, including colonoscopy, mammography, and any other tests your risk profile warrants.

Source: Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., . . . Leach, S. D. (2017). Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551(7681), 512–516. https://doi.org/10.1038/nature24462